Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden.

Simpson KN, Hanson KA, Harding G, Haider S, Tawadrous M, Khachatryan A, Pashos CL, Wu AW.

AIDS Care. 2014 Apr;26(4):466-75. doi: 10.1080/09540121.2013.841825. Epub 2013 Oct 10. Review.

PMID:
24111805
2.

Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review.

Simpson KN, Hanson KA, Harding G, Haider S, Tawadrous M, Khachatryan A, Pashos CL, Wu AW.

Health Qual Life Outcomes. 2013 Oct 3;11:164. doi: 10.1186/1477-7525-11-164. Review.

3.

Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.

Schiller DS, Youssef-Bessler M.

Clin Ther. 2009 Apr;31(4):692-704. doi: 10.1016/j.clinthera.2009.04.020. Review.

PMID:
19446143
4.

Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.

Humphreys EH, Chang LW, Harris J.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD006517. doi: 10.1002/14651858.CD006517.pub3. Review.

PMID:
20556768
5.

HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.

Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B.

Int J STD AIDS. 2007 Dec;18(12):832-4.

PMID:
18073016
6.

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.

Tambuyzer L, Azijn H, Rimsky LT, Vingerhoets J, Lecocq P, Kraus G, Picchio G, de Béthune MP.

Antivir Ther. 2009;14(1):103-9.

PMID:
19320243
7.

Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.

Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, Brumme ZL, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):395-402.

PMID:
14640386
8.
9.

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ.

AIDS. 2002 Oct 18;16(15):F41-7.

PMID:
12370521
10.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
11.

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V.

J Med Virol. 2001 Nov;65(3):445-8.

PMID:
11596076
12.

Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.

Aragão F, Vera J, Vaz Pinto I.

PLoS One. 2012;7(9):e44774. doi: 10.1371/journal.pone.0044774. Epub 2012 Sep 17.

14.

Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.

Spaulding A, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD008651. doi: 10.1002/14651858.CD008651. Review.

PMID:
20687097
15.
16.

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA; California Collaborative Treatment Group.

AIDS. 2002 Oct 18;16(15):F33-40.

PMID:
12370520
17.

A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.

Shey M, Kongnyuy EJ, Shang J, Wiysonge CS.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005481. doi: 10.1002/14651858.CD005481.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;3:CD005481.

PMID:
19588374
18.

Therapeutic drug monitoring of antiretrovirals for people with HIV.

Kredo T, Van der Walt JS, Siegfried N, Cohen K.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007268. doi: 10.1002/14651858.CD007268.pub2. Review.

PMID:
19588422
19.

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.

Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, Israelski DM, Hellmann N, Petropoulos C, Whitcomb J.

AIDS. 2001 Jun 15;15(9):1125-32.

PMID:
11416714
20.

Supplemental Content

Support Center